liu.seSearch for publications in DiVA
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
RAB6C is an independent prognostic factor of estrogen receptor-positive/progesterone receptor-negative breast cancer
Linköpings universitet, Institutionen för biomedicinska och kliniska vetenskaper, Avdelningen för kirurgi, ortopedi och onkologi. Linköpings universitet, Medicinska fakulteten. Region Östergötland, Centrum för verksamhetsstöd och utveckling, Regionalt Cancercentrum.
Linköpings universitet, Institutionen för klinisk och experimentell medicin. Linköpings universitet, Medicinska fakulteten. Region Östergötland, Centrum för kirurgi, ortopedi och cancervård, Onkologiska kliniken US.
Linköpings universitet, Institutionen för biomedicinska och kliniska vetenskaper, Avdelningen för kirurgi, ortopedi och onkologi. Linköpings universitet, Medicinska fakulteten.
Karolinska Inst, Sweden.
Vise andre og tillknytning
2020 (engelsk)Inngår i: Oncology Letters, ISSN 1792-1074, E-ISSN 1792-1082, Vol. 19, nr 1, s. 52-60Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

The majority of breast cancer tumors are estrogen receptor-positive (ER+) and can be treated with endocrine therapy. However, certain patients may exhibit a good prognosis without systemic treatment. The aim of the present study was to identify novel prognostic factors for patients with ER breast cancer tumors using gene copy data, and to investigate if these factors have prognostic value in subgroups categorized by progesterone receptor status (PR). Public data, including the whole genome gene copy data of 199 systemically untreated patients with ER+ tumors, were utilized in the present study. To assess prognostic value, patients were divided into two groups using the median gene copy number as a cut-off for the SNPs that were the most variable. One SNP was identified, which indicated that the Ras-related protein Rab-6C (RAB6C) gene may exhibit prognostic significance. Therefore, RAB6C protein expression was subsequently investigated in a second independent cohort, consisting of 469 systematically untreated patients (of which 310 were ER+) who received long term follow-up. In the public data set, a distant recurrence risk reduction of 55% was determined for copy numbers above the median value of RAB6C compared with numbers below [multivariable adjusted hazard ratio (HR), 0.45; 95% CI 0.28-0.72; P=0.001)]. It was also more pronounced in the ER+/PR- subgroup (HR, 0.15; 95% CI, 0.05-0.46; P=0.001). In the second cohort, patients of the ER+/PR- subgroup who exhibited high RAB6C expression had a reduced distant recurrence risk (HR, 0.17; 95% CI, 0.05-0.60; P=0.006). However, this was not identified among ER+/PR- tumors (HR, 1.31; 95% CI, 0.69-2.48; P=0.41). The results of the present study indicated that RAB6C serves as an independent prognostic factor of distant recurrence risk in systemically untreated patients with an ER+/PR- tumor.

sted, utgiver, år, opplag, sider
SPANDIDOS PUBL LTD , 2020. Vol. 19, nr 1, s. 52-60
Emneord [en]
breast neoplasm; Ras-related protein Rab-6C; gene copy number; prognostic; estrogen receptor; progesterone receptor
HSV kategori
Identifikatorer
URN: urn:nbn:se:liu:diva-163461DOI: 10.3892/ol.2019.11109ISI: 000508369500005PubMedID: 31897114OAI: oai:DiVA.org:liu-163461DiVA, id: diva2:1393696
Merknad

Funding Agencies|Swedish Cancer SocietySwedish Cancer Society [17-0479]; Cancer Research Foundations of Radiumhemmet; Cancer Society in Stockholm; King Gustav V Jubilee Clinical Research Foundation [181093]; Onkologiska klinikerna i Linkopings forskningsfond [2016-06-21]; ALF grants Region Ostergotland [LIO-795201]; County Council of Ostergotland [LIO-625491]

Tilgjengelig fra: 2020-02-17 Laget: 2020-02-17 Sist oppdatert: 2020-03-05

Open Access i DiVA

fulltext(439 kB)24 nedlastinger
Filinformasjon
Fil FULLTEXT01.pdfFilstørrelse 439 kBChecksum SHA-512
834a27a0cff8ababab1dbc528a1205703ad0682399f533bda3177f43f52d3a061a9ed6f2b2f0f71637ad20fce07e0bbbb1a274aae108f745af2663e908ee1f1c
Type fulltextMimetype application/pdf

Andre lenker

Forlagets fulltekstPubMed

Søk i DiVA

Av forfatter/redaktør
Fohlin, HelenaBekkhus, ToveSandström, JosefineNordenskjöld, BoCarstensen, JohnStål, Olle
Av organisasjonen
I samme tidsskrift
Oncology Letters

Søk utenfor DiVA

GoogleGoogle Scholar
Totalt: 24 nedlastinger
Antall nedlastinger er summen av alle nedlastinger av alle fulltekster. Det kan for eksempel være tidligere versjoner som er ikke lenger tilgjengelige

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 77 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf